Lycia Therapeutics
Research - South San Francisco, California, US
Lycia Therapeutics Employees
Lycia Therapeutics Senior Management
Lycia Therapeutics Details
Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.
Lycia Therapeutics Technologies
Email Providers
Outlook
CMS
WordPress.org
Recruitment
Lever
Hosting
Flywheel
Other
Mobile Friendly